Basic science research on erectile physiology has focused on the pathogenesis of erectile
dysfunction (ED) and has provided convincing evidence that ED is predominately a disease …

Introduction: Phosphodiesterase type 5 inhibitors (PDE5-i) are used for the oral treatment of
erectile dysfunction (ED). Since the launch of sildenafil more than 15 years ago, new …

Abstract The Nobel Prize winning discovery of nitric oxide (NO) in 1986 was the starting
point for a new innovation in drug discovery. NO acting as a mediator at different …

Abstract Background The phosphodiesterase-5 (PDE5) inhibitors that have been available
for nearly 20 years are highly effective in treating erectile dysfunction and have been …

ABSTRACT Background Nowadays, Oral phosphodiesterase type 5 inhibitors (PDE5Is) are
widely used for the treatment of erectile dysfunction (ED). However, these drugs have …

Introduction Erectile dysfunction (ED) is a condition that affects millions of men worldwide
and is characterized by the inability to achieve or maintain an erection for satisfactory sexual …

Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

Phosphodiesterase 5 inhibitors, such as sildenafil, vardenafil and tadalafil, are now
approved for the treatment of erectile dysfunction. They inhibit the cGMP-specific isoform 5 of …

Objectives The use of inhibitors of phosphodiesterase 5 (PDE5) has been suggested to treat
symptoms of female sexual dysfunction (FSD). Nonetheless, there has been a relatively low …

Since the early 1980s, research on the mechanisms of penile erection has done much to
clarify erectile physiology and pathophysiology. More recent studies have identified the …